Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

MoonLake Immunotherapeutics (MLTX) Profit After Tax (2021 - 2026)

MoonLake Immunotherapeutics' Profit After Tax history spans 6 years, with the latest figure at -$69.7 million for Q1 2026.

  • Quarterly Profit After Tax fell 71.87% to -$69.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$261.9 million through Mar 2026, down 78.11% year-over-year, with the annual reading at -$230.3 million for FY2025, 93.65% down from the prior year.
  • Profit After Tax came in at -$69.7 million for Q1 2026, down from -$65.4 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of -$7.4 million in Q4 2023 to a low of -$70.7 million in Q3 2025.
  • The 5-year median for Profit After Tax is -$17.4 million (2022), against an average of -$31.1 million.
  • The largest YoY upside for Profit After Tax was 68.11% in 2022 against a maximum downside of 4415.6% in 2022.
  • MoonLake Immunotherapeutics' Profit After Tax stood at -$17.1 million in 2022, then surged by 56.53% to -$7.4 million in 2023, then crashed by 513.23% to -$45.6 million in 2024, then tumbled by 43.47% to -$65.4 million in 2025, then dropped by 6.54% to -$69.7 million in 2026.
  • Per Business Quant, the three most recent readings for MLTX's Profit After Tax are -$69.7 million (Q1 2026), -$65.4 million (Q4 2025), and -$70.7 million (Q3 2025).